Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

NVS vs GNPX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NVS Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

NVS Overall Winner 6-Pillar Tally: NVS 5 – 0 GNPX (1 Tie) Matrix Metrics: NVS 9 – 1 GNPX

As of Nov 20, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over Genprex, Inc. (GNPX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NVS carries a Unified Composite Score of 37.0/100 (SELL) at $150.47 (15.2x Forward P/E, 34.0% operating margin), whereas GNPX carries 42.2/100 (HOLD) at $1.45 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While GNPX currently prints a higher short-term Unified Composite Score (42.2/100 HOLD vs. NVS 37.0/100 SELL), NVS captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 0.0% operating margin) and revenue trajectory (+4.7% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: NVS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.7); meanwhile GNPX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NVS vs GNPX
NVS NYSE Head-to-Head Winner
Novartis AG
Pharmaceutical Preparations
$150.47
-0.5% 1D
Market Cap $285.6B
TTM Revenue $40.5B
Forward P/E 15.2x
Beta / 30D Vol 0.32β · 28% Vol
Unified Composite Score
37.0 / 100 SELL
Tech 20.0 Fund 34.0 Flow 50.0 Mom 36.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 38.7 · SMA20: $159.16 · SMA50: $150.46
GNPX NASDAQ
Genprex, Inc. Common Stock
Pharmaceutical Preparations
$1.45
-13.17% 1D
Market Cap $2.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -4.68β · 96% Vol
Unified Composite Score
42.2 / 100 HOLD
Tech 25.0 Fund 47.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -22.2%), weak momentum, RSI 27
RSI-14: 26.6 · SMA20: $2.00 · SMA50: $2.48

6-Pillar Scorecard Institutional Category Breakdown (NVS 5 – 0 GNPX)

Columns: Metric · NVS · GNPX
1. Valuation Multiples NVS
Forward P/E 15.2x N/M
Trailing P/E 28.9x N/M
PEG Ratio 3.69x N/M
EV / Revenue 7.1x N/M
2. Growth & Scale NVS
Revenue Growth (YoY) +4.7% +0.0%
Earnings Growth (YoY) -68.8% +0.0%
TTM Revenue (USD) $40.5B N/A
Market Cap $285.6B $2.2M
3. Profitability & Quality NVS
Gross Margin 75.2% N/A
Operating Margin 34.0% 0.0%
Net Profit Margin 17.5% 0.0%
Return on Equity (ROE) 24.3% -233.7%
4. Balance Sheet & Cash Flow NVS
Cash Generation (TTM) $17.0B EBITDA N/A
Cash Flow Margin 42.0% EBITDA Mgn N/A
Net Cash / Leverage $19.71 Book/Sh · 24.3% ROE $11.26 Book/Sh · -233.7% ROE
Dividend Yield 3.13% None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 16.9% (6th %ile) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat NVS
OpEx & R&D Intensity 41.2% of Rev ($16.7B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - General Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NVS (9) vs GNPX (1)
Institutional Metric NVS GNPX Criterion Row Edge
Market Capitalization
Scale
$285.6B $2.2M Larger Scale NVS
Trailing P/E Ratio
Valuation
28.9x N/M Lower Multiple NVS
Forward P/E Ratio
Valuation
15.2x N/M Lower Multiple NVS
Revenue Growth (YoY)
Growth
+4.7% +0.0% Higher Growth NVS
Operating Margin (TTM)
Profitability
34.0% 0.0% Higher Margin NVS
Net Profit Margin
Profitability
17.5% 0.0% Higher Margin NVS
Return on Equity (ROE)
Capital Efficiency
24.3% -233.7% Higher ROE NVS
52-Week Range Position
Momentum
58% ($123–$170) 11% ($0–$10) Stronger Trend NVS
Beta / 30D Volatility
Risk Regime
0.32β · 28% Vol -4.68β · 96% Vol Lower Realized Risk NVS
Unified Institutional Score
Composite Signal
37.0 / 100 (SELL) 42.2 / 100 (HOLD) Higher Composite GNPX
Trailing 12M Revenue (USD)
Operating Scale
$40.5B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.69x PEG · 7.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$17.0B EBITDA ($19.71 Book/Sh · 24.3% ROE) N/A ($11.26 Book/Sh · -233.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NVS +23.06 pp
NVS: -3.71% · GNPX: -26.77%
3M Horizon NVS +59.15 pp
NVS: -4.78% · GNPX: -63.93%
6M Horizon GNPX +77.6 pp
NVS: -1.01% · GNPX: +76.59%
1Y Horizon NVS +74.78 pp
NVS: +18.19% · GNPX: -56.59%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs GNPX. Trailing 12-month operating profitability (NVS 34.0% vs GNPX 0.0%) and valuation multiples (NVS 15.2x vs GNPX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

NVS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$40.5B
Gross Margin75.2%
Op. Margin34.0%
ROE / Fwd P/E24.3% · 15.2x
GNPX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-233.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NVS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 16.9%
IV Percentile 6th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GNPX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GNPX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NVS Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $285.6B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment 41.2% of Rev ($16.7B)
90D Engineering Disclosures 0 Published
GNPX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NVS vs GNPX Key Questions & Quantitative Answers

As of Nov 20, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over Genprex, Inc. (GNPX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NVS carries a Unified Composite Score of 37.0/100 (SELL) at $150.47 (15.2x Forward P/E, 34.0% operating margin), whereas GNPX carries 42.2/100 (HOLD) at $1.45 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While GNPX currently prints a higher short-term Unified Composite Score (42.2/100 HOLD vs. NVS 37.0/100 SELL), NVS captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 0.0% operating margin) and revenue trajectory (+4.7% vs. +0.0% YoY). Technical & Structure Timing Caution: NVS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.7); meanwhile GNPX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NVS leads the Growth & Scale pillar: NVS posts +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin), compared with GNPX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, NVS generates $40.5B in USD-normalized revenue versus N/A for GNPX. In operating R&D and SG&A reinvestment, NVS deploys 41.2% of Rev ($16.7B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GNPX.

NVS screens cheaper on headline valuation multiples. NVS trades at 15.2x Forward P/E, 28.9x Trailing P/E, 3.69x PEG, and 7.1x EV/Revenue (42.0% EBITDA margin), whereas GNPX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVS (24.3% ROE) versus GNPX (-233.7% ROE) capital efficiency.

In options market volatility and institutional positioning, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.32β · 28% Vol realized risk). By comparison, GNPX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-4.68β · 96% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.